Clinical Trial Update: RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study evaluating RO5126766 in patients with advanced KRAS-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RO5126766 (RO5126766)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED